Prof Andrea Sartore-Bianchi (NTRK CONNECT) has developed this resource with COR2ED.
Prof Andrea Sartore-Bianchi (NTRK CONNECT) has developed this resource with COR2ED.
Andrea Sartore-Bianchi is the Director of the Division of Clinical Research and Innovation at Grande Ospedale Metropolitano Niguarda in Milano, Italy, and Associate Professor of Oncology at the University of Milano. He received his MD and postgraduate degree in Oncology at the University of Pavia, Italy, and subsequently conducted preclinical research at Brown University, Providence, RI, USA.
His main clinical and research interests include precision oncology and the treatment of gastrointestinal cancers, particularly colorectal carcinomas, focusing on biomarkers of sensitivity/resistance to targeted therapies. He is principal and co-investigator in Phase I-III clinical trials for solid tumours and carried out initial studies paving the way for the use of RAS and Her2 as tumor tissue/ctDNA biomarkers in colorectal cancer. He has published 200 peer-reviewed articles in various medical journals with a H-index of 62 (Scopus).
Amgen, Bayer, Sanofi and Servier Pharmaceuticals.
Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer
Αναλύσεις από καταξιωμένους ειδικούς ιατρούς. Πλοηγηθείτε στις καρτέλες για να επιλέξετε ένα επεισόδιο podcast
How will the latest Dato-DXd data impact treatment strategies for HR+/HER2− mBC?
Understanding the role of molecular subtypes in guiding treatment selection
Uznani eksperci dzielą się swoimi spostrzeżeniami. Kliknij na odpowiednią zakładkę, aby wybrać odcinek podcastu.